title: Improvement in the Outcome of Invasive Aspergillosis in a Pediatric Hematology Department: A 10-Year Review.
abstract: BACKGROUND
  Invasive aspergillosis (IA) is associated with a high mortality rate despite the introduction of new antifungal agents. Several therapeutic strategies have been proposed to improve mortality rates in IA, including combination of drugs.
  
  
  METHODS
  Here, we report the outcome of treatments based on a combination of antifungal agents on IA, including voriconazole and liposomal amphotericin B, in a pediatric population from 2001 to 2010. Our population included children with diverse hematological diseases or with bone marrow transplantation.
  
  
  RESULTS
  Over a 10-year period, we diagnosed 19 cases (2,8%) of invasive pulmonary aspergillosis with an overall survival rate of 58%.
  
  
  CONCLUSIONS
  Compared with the previous study conducted from 1986 to 2000, the overall survival rate (bone marrow transplantation excluded) greatly improved (12.5% to 58%), especially for patients treated for acute leukemia.
authors.affiliation: *Institute of Pediatric Hematology and Oncology, Hospices Civils de Lyon, Claude Bernard Lyon I University ‡Malaria Research Unit, ICBMS, CNRS UMR 5246, University Lyon 1 †Medical Mycology and Parasitology Unit, IP2M §Department of Pediatric Radiology, Women-Mother and Child Hospital, Hospices Civils de Lyon, Lyon, France.
authors.forename: Carine
authors.initials: C
authors.lastname: Domenech
authors.forename: Charline
authors.initials: C
authors.lastname: Leick-Courtois
authors.forename: Anne-Lise
authors.initials: AL
authors.lastname: Bienvenu
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Pracros
authors.forename: Stéphane
authors.initials: S
authors.lastname: Picot
authors.forename: Nathalie
authors.initials: N
authors.lastname: Bleyzac
authors.forename: Yves
authors.initials: Y
authors.lastname: Bertrand
mesh_terms: D000293:Adolescent; D000935:Antifungal Agents / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D005260:Female; D006405:Hematology / Q000706:statistics & numerical data; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D016867:Immunocompromised Host; D007223:Infant; D055744:Invasive Pulmonary Aspergillosis / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality*; D007938:Leukemia / Q000150:complications / Q000188:drug therapy; D008297:Male; D010372:Pediatrics / Q000706:statistics & numerical data; D012189:Retrospective Studies
chemical_list: D000935:Antifungal Agents; D000970:Antineoplastic Agents